Edition:
United Kingdom

Insmed Inc (INSM.OQ)

INSM.OQ on NASDAQ Stock Exchange Global Select Market

24.05USD
5:22pm GMT
Change (% chg)

$-0.17 (-0.70%)
Prev Close
$24.22
Open
$24.31
Day's High
$24.48
Day's Low
$23.97
Volume
65,785
Avg. Vol
277,792
52-wk High
$33.94
52-wk Low
$11.49

Select another date:

Wed, Jan 24 2018

BRIEF-Insmed Prices Public Offering Of $400 Mln Principal Amount Of Its Convertible Senior Notes

* INSMED ANNOUNCES PRICING OF PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES

BRIEF-Insmed Announces Proposed Public Offering Of Convertible Senior Notes

* INSMED ANNOUNCES PROPOSED PUBLIC OFFERING OF CONVERTIBLE SENIOR NOTES

BRIEF-Insmed Q3 loss per share $0.69

* Insmed reports third quarter 2017 financial results and provides business update

BRIEF-Arsanis appoints Michael Gray as chief financial officer

* Arsanis announces appointments of Chip Clark and David Mcgirr to board of directors and promotion of Michael Gray to chief operating officer and chief financial officer Source text for Eikon: Further company coverage:

BRIEF-Insmed announces proposed public offering of common stock

* Insmed Inc - ‍Has commenced an underwritten public offering of $250 million of shares of its common stock​

Insmed shares skyrocket after lung drug meets key study's main goal

Shares of Insmed Inc more than doubled on Tuesday after the company said its drug to treat adults with a rare lung disorder met the main goal in a key study, leading it to apply for accelerated approval.

UPDATE 2-Insmed shares skyrocket after lung drug meets key study's main goal

* Shares soar as much as 140 pct (Adds details, analyst comments, updates shares)

Insmed's lung drug meets main goal in late-stage study

Sept 5 Insmed Inc said its drug for the treatment of a rare and serious lung disorder met the main goal in a late-stage study, sending its shares up 75 percent in premarket trading on Tuesday.

BRIEF-Insmed announces positive top-line results from phase 3 convert study of ALIS

* Insmed announces positive top-line results from phase 3 convert study of ALIS (amikacin liposome inhalation suspension) in adult patients with treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by mycobacterium avium complex (MAC)

Select another date: